Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023

Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India

The drug will be marketed by Sun Pharma under the brand name RYTSTAT

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter

Glenmark receives ANDA approval for Apremilast Tablets

Glenmark's current portfolio consists of 188 products authorized for distribution in the US

Ipca appoints Hitesh Kumar Maheshwari as President – R&D (Formulations)

He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company

Zydus appoints Punit Patel as President and CEO, Americas

Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace

Evonik and Shandong Vland Biotech form JV in China with focus on gut health products for animals

Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally